Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $55.82 USD
Change Today +0.08 / 0.14%
Volume 333.6K
ALKS On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 11:43 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

alkermes plc (ALKS) Key Developments

Alkermes plc Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reiterates Earnings Guidance for the Full Year of 2015

Alkermes plc reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company’s adjusted net income totaled $9.2 million or $0.06 per basic and diluted share, down from $16.2 million or $0.11 per basic and diluted share a year earlier. On a GAAP-basis, the net loss widened to $30.7 million or $0.21 per basic and diluted share from $24.4 million or $0.17 per basic and diluted share in the year-ago period. Revenues totaled $161.214 million, up 23.8% year-on-year compared to $130.212 million a year ago. Loss before income taxes was $30.147 million compared to $20.588 million a year ago. Capital expenditures were $10.710 million compared to $5.685 million a year ago. Free cash flow was $1.553 million compared to $10.466 million a year ago. For fiscal 2015, the company continues to expect a non-GAAP net loss of $0.37 to $0.50 per share on revenues of $600 million to $630 million.

Alkermes plc to Report Q1, 2015 Results on Apr 30, 2015

Alkermes plc announced that they will report Q1, 2015 results at 8:30 AM, US Eastern Standard Time on Apr 30, 2015

Alkermes plc, Q1 2015 Earnings Call, Apr 30, 2015

Alkermes plc, Q1 2015 Earnings Call, Apr 30, 2015

Alkermes Plans Phase 1 Clinical Study of Immuno-Oncology Drug Candidate in Third Quarter of 2015

Alkermes announced that based on preclinical data from studies of the company's selective effector cell activator (SECA) immuno-oncology drug candidate, RDB 1450, it plans to initiate a phase 1 clinical study in the third quarter of 2015.

Alkermes plc Announces Positive Results from Complete Six-Month Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia

Alkermes plc announced the positive topline results from the complete, six-month, randomized, dose-ranging phase 2 study of ALKS 3831, an investigational, novel, oral atypical antipsychotic drug candidate designed to be a broad-spectrum treatment for schizophrenia. The study was designed in two stages: for the initial three months, patients were randomized to receive olanzapine or one of three doses of ALKS 3831, and antipsychotic efficacy and weight gain were assessed. Positive topline data from this stage were announced in January 2015, showing that ALKS 3831 met the study’s primary endpoint, demonstrating antipsychotic efficacy equivalent to olanzapine, as well as key secondary endpoints showing ALKS 3831’s favorable effects on weight gain compared to olanzapine. For the second three months, all patients who received ALKS 3831 during the initial three months continued to receive ALKS 3831, and patients who had received olanzapine were switched to ALKS 3831. Data from the completed study support and extend the initial positive results showing ALKS 3831’s favorable efficacy and mean weight gain profile and show for the first time that switching patients from olanzapine to ALKS 3831 resulted in a cessation of mean weight gain. For patients who received ALKS 3831 throughout the entire six-month treatment period, efficacy, as evaluated by the reduction from baseline in Positive and Negative Syndrome Scale (PANSS) total scores, was equivalent to olanzapine during the initial three-month stage and this efficacy was maintained throughout the second three-month stage (change in PANSS total score from Week 12 to Week 24 was -1.7 points, 95% confidence interval (CI): (-2.7, -0.7)). The beneficial effect on weight gain observed during the initial three months was also maintained during the second three-month stage. Mean percent change in body weight, from Week 12 to Week 24, was 0.5%, 95% CI: (-0.2%, 1.2%), indicating a consistent and durable blockade of olanzapine-induced weight gain. Patients who received olanzapine in the initial three-month stage were transitioned to receive ALKS 3831 for the second three-month stage. For these patients, efficacy as evaluated by PANSS scores was maintained (change in PANSS total score from Week 12 to Week 24 was -1.3 points, 95% CI: (-3.3, 0.7)). During the initial three-month stage, this patient population experienced significant weight gain, consistent with previously reported studies of olanzapine (mean percent change in body weight from baseline was 4.3%, 95% CI: (2.4%, 6.2%)). When these patients were transitioned to ALKS 3831 in the second three-month stage, overall no further weight gain was observed (mean percent change in body weight from Week 12 to Week 24 was 0.1%, 95% CI: (-1.0%, 1.2%)).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALKS:US $55.81 USD +0.07

ALKS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cosmo Pharmaceuticals SA SFr.158.10 CHF +0.50
Depomed Inc $23.66 USD +0.2978
Emergent Biosolutions Inc $30.94 USD +0.31
Jazz Pharmaceuticals PLC $176.71 USD +0.29
Pacira Pharmaceuticals Inc/DE $67.28 USD +1.50
View Industry Companies
 

Industry Analysis

ALKS

Industry Average

Valuation ALKS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.1x
Price/Book 6.0x
Price/Cash Flow 350.5x
TEV/Sales 11.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.